Literature DB >> 11145600

Human ovarian cancer and cisplatin resistance: possible role of inhibitor of apoptosis proteins.

J Li1, Q Feng, J M Kim, D Schneiderman, P Liston, M Li, B Vanderhyden, W Faught, M F Fung, M Senterman, R G Korneluk, B K Tsang.   

Abstract

The inhibitor of apoptosis proteins (IAPs) constitutes a family of highly conserved apoptosis suppressor proteins that were originally identified in baculoviruses. Although IAP homologs have recently been demonstrated to suppress apoptosis in mammalian cells, their expression and role in human ovarian epithelial cancer and chemotherapy resistance are unknown. In the present study we used cisplatin-sensitive and -resistant human ovarian surface epithelial (hOSE) cancer cell lines and adenoviral antisense and sense complementary DNA expression to examine the role of IAP in the regulation of apoptosis in human ovarian cancer cells and chemoresistance. Antisense down-regulation of X-linked inhibitor of apoptosis protein (Xiap), but not human inhibitor of apoptosis protein-2 (Hiap-2), induced apoptosis in cisplatin-sensitive and, to a lesser extent, in -resistant cells. Cisplatin consistently decreased Xiap content and induced apoptosis in the cisplatin-sensitive, but not cisplatin-resistant, cells. Hiap-2 expression was either unaffected or inhibited to a lesser extent. The inhibition of IAP protein expression and induction of apoptosis by cisplatin was time and concentration dependent. Infection of cisplatin-sensitive cells with adenoviral sense Xiap complementary DNA resulted in overexpression of Xiap and markedly attenuated the ability of cisplatin to induce apoptosis. Immunohistochemical localization of the IAPs in hOSE tumors demonstrated the presence of Xiap and Hiap-2, with their levels being highest in proliferative, but not apoptotic, epithelial cells. These studies indicate that Xiap is an important element in the control of ovarian tumor growth and may be a point of regulation for cisplatin in the induction of apoptosis. These results suggest that the ability of cisplatin to down-regulate Xiap content may be an important determinant of chemosensitivity in hOSE cancer.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11145600     DOI: 10.1210/endo.142.1.7897

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  51 in total

1.  An unconventional IAP-binding motif revealed by target-assisted iterative screening (TAIS) of the BIR3-cIAP1 domain.

Authors:  Alexei Kurakin; Dale E Bredesen
Journal:  J Mol Recognit       Date:  2007 Jan-Feb       Impact factor: 2.137

2.  Combined treatment with TRAIL and PPARγ ligands overcomes chemoresistance of ovarian cancer cell lines.

Authors:  Karen Bräutigam; Julia Biernath-Wüpping; Dirk O Bauerschlag; Constantin S von Kaisenberg; Walter Jonat; Nicolai Maass; Norbert Arnold; Ivo Meinhold-Heerlein
Journal:  J Cancer Res Clin Oncol       Date:  2010-09-29       Impact factor: 4.553

Review 3.  Chemosensitization of tumors by resveratrol.

Authors:  Subash C Gupta; Ramaswamy Kannappan; Simone Reuter; Ji Hye Kim; Bharat B Aggarwal
Journal:  Ann N Y Acad Sci       Date:  2011-01       Impact factor: 5.691

4.  Lipophilic aroylhydrazone chelator HNTMB and its multiple effects on ovarian cancer cells.

Authors:  Kyu Kwang Kim; Thilo S Lange; Rakesh K Singh; Laurent Brard
Journal:  BMC Cancer       Date:  2010-02-25       Impact factor: 4.430

Review 5.  Potential therapeutic benefits of strategies directed to mitochondria.

Authors:  Amadou K S Camara; Edward J Lesnefsky; David F Stowe
Journal:  Antioxid Redox Signal       Date:  2010-08-01       Impact factor: 8.401

6.  Overcoming cancer therapy resistance by targeting inhibitors of apoptosis proteins and nuclear factor-kappa B.

Authors:  Yao Dai; Theodore S Lawrence; Liang Xu
Journal:  Am J Transl Res       Date:  2009-01-01       Impact factor: 4.060

7.  Mifepristone abrogates repopulation of ovarian cancer cells in between courses of cisplatin treatment.

Authors:  Elizabeth M Freeburg; Alicia A Goyeneche; Carlos M Telleria
Journal:  Int J Oncol       Date:  2009-03       Impact factor: 5.650

Review 8.  Oncogenes associated with drug resistance in ovarian cancer.

Authors:  Xia Liu; Yutao Gao; Yi Lu; Jian Zhang; Li Li; Fuqiang Yin
Journal:  J Cancer Res Clin Oncol       Date:  2014-07-06       Impact factor: 4.553

9.  Liposomal honokiol, a promising agent for treatment of cisplatin-resistant human ovarian cancer.

Authors:  Hong Luo; Qian Zhong; Li-juan Chen; Xiao-rong Qi; A-fu Fu; Han-shuo Yang; Fan Yang; Hong-gang Lin; Yu-quan Wei; Xia Zhao
Journal:  J Cancer Res Clin Oncol       Date:  2008-03-19       Impact factor: 4.553

10.  MLH1 expression sensitises ovarian cancer cells to cell death mediated by XIAP inhibition.

Authors:  X Ding; A B Mohd; Z Huang; T Baba; M Q Bernardini; H K Lyerly; A Berchuck; S K Murphy; A B Buermeyer; G R Devi
Journal:  Br J Cancer       Date:  2009-07-21       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.